KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Leases: 2012-2024

Historic Current Leases for Novavax (NVAX) over the last 7 years, with Dec 2024 value amounting to $7.0 million.

  • Novavax's Current Leases fell 47.95% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 47.95%. This contributed to the annual value of $7.0 million for FY2024, which is 75.07% down from last year.
  • Latest data reveals that Novavax reported Current Leases of $7.0 million as of FY2024, which was down 75.07% from $28.1 million recorded in FY2023.
  • Novavax's Current Leases' 5-year high stood at $161.5 million during FY2021, with a 5-year trough of $7.0 million in FY2024.
  • For the 3-year period, Novavax's Current Leases averaged around $26.4 million, with its median value being $28.1 million (2023).
  • As far as peak fluctuations go, Novavax's Current Leases skyrocketed by 47.31% in 2021, and later crashed by 75.07% in 2024.
  • Yearly analysis of 5 years shows Novavax's Current Leases stood at $109.6 million in 2020, then soared by 47.31% to $161.5 million in 2021, then tumbled by 72.72% to $44.1 million in 2022, then plummeted by 36.18% to $28.1 million in 2023, then slumped by 75.07% to $7.0 million in 2024.